<DOC>
	<DOCNO>NCT00183833</DOCNO>
	<brief_summary>This study people solid tumor cancer standard chemotherapy drug work . The purpose research evaluate side effect Xeloda ( also call capecitabine ) combination new anticancer agent call Gleevec ( also call imatinib mesylate ) . Xeloda anticancer drug , take mouth . The active ingredient well-studied cancer drug call 5-FU . Xeloda approve FDA treatment colon cancer . Gleevec approve US treatment patient leukemia call CML ( increase white blood cell ) failure standard therapy . It also approve FDA patient Gastrointestinal Stromal Tumors ( rare tumor digestive tract ) . This study test much Gleevec safely give Xeloda . Xeloda give recommend dose colorectal cancer Gleevec give increase amount .</brief_summary>
	<brief_title>Study Xeloda Gleevec Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically cytologically confirm metastatic unresectable solid tumor standard curative palliative measure exist longer effective . SWOG performance status 02 . ANC great 1500 , platelet great 100,000 . Total bilirubin le 2 x upper limit normal , less 3 x upper limit normal patient liver metastasis . Transaminase ( AST and/or ALT ) less 2 x upper limit normal le 3 x upper limit normal patient liver metastasis . Serum creatinine le 1.25 x institutional upper limit normal . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Patient receive investigational agent within 28 day first day study drug dose . Patient another primary malignancy except primary malignancy neither currently clinically significant require active intervention . Patient another severe and/or lifethreatening medical disease . Patient acute know chronic liver disease ( e.g. , chronic active hepatitis , cirrhosis ) . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . Patient receive chemotherapy within 4 week ( 6 week nitrosourea , mitomycinC antibody therapy ) prior study entry unless urgent enrollment need approve Novartis . Patient major surgery within 2 week prior study entry . Patients symptomatic brain metastasis . Patient Grade III/IV cardiac problem define New York Heart Association Criteria ( e.g . congestive heart failure , myocardial infarction within 6 month study ) Medical , social psychological factor interfere compliance . Patients therapeutic coumadin therapy . Patients routine systemic corticosteroid therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>phase 1</keyword>
	<keyword>phase I</keyword>
	<keyword>phase one</keyword>
	<keyword>colon cancer</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>